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Abstract. Melanoma cells often express platelet-activating 
factor receptor (PAF-R), which has been demonstrated to 
increase metastatic behavior. However, the effect of PAF-R 
on the responsiveness of melanoma to naturally occurring 
cytotoxic agents remains to be elucidated. The present study 
aimed to determine the relative cytotoxicity and mechanism 
of benzyl isothiocyanate (BITC), a component of cruciferous 
vegetables, in melanoma cells expressing PAF-R. To evaluate 
the importance of PAF-R signaling in melanoma cell growth, 
PAF-R-negative murine B16F10 cells were transduced with 
a retrovirus containing the cDNA for PAF-R to generate 
cells stably expressing PAF-R (B16-PAF-R) or an empty 
vector (MSCV) to generate PAF-R-deficient B16-MSCV 
control cells. Activation of PAF-R, using the PAF-R agonist, 
1-hexadecyl-2-N-methylcarbamoyl-3-glycerophosphocholine, 
induced an increase in the proliferation of B16-PAF-R cells 
compared with the B16-MSCV cells. Reverse transcription 
quantitative polymerase chain reaction revealed the presence 
of functional PAF-R in human melanoma SK23MEL cells, but 
not in SK5MEL cells. The present study investigated the effect 
of BITC treatments on the survival of murine and human mela-
noma cells, in the presence or absence of functional PAF-R. 
The results revealed that treatment with BITC decreased the 
survival rate of the PAF-R-positive and negative murine and 
human melanoma cells. However, the expression of PAF-R 
substantially augmented BITC-mediated cytotoxicity in the 
PAF-R-positive cells at lower concentrations compared with 
the PAF-R-negative cells. In order to determine the underlying 
mechanism, flow cytometric analysis was used, which demon-
strated a significant increase in the generation of reactive 
oxygen species (ROS) in the B16-PAF-R cells compared with 
the B16-MSCV cells, which enhanced apoptosis by BITC, as 
measured by increased caspase-3/7 luminescence. Notably, the 
BITC-mediated decreased cell survival rate, increased ROS 
and increased apoptosis in the B16‑PAF‑R cells were signifi-
cantly attenuated by the antioxidant, vitamin C, indicating 
ROS involvement. Additionally, the WEB2086 PAF-R antago-
nist, inhibited the BITC-mediated enhancement of apoptosis 
in the B16-PAF-R cells, indicating a role for PAF-R-signaling 
in the BITC‑mediated effects. These findings indicated that 
the selectivity of BITC towards PAF-R in melanoma offers 
a promising chemopreventive agent for PAF-R-positive mela-
noma treatment.
Introduction
The incidence of malignant melanoma is rapidly increasing, with 
the estimated annual mortality rate of >9,000 in the USA (1,2). 
Melanoma cells often express receptors for multiple growth 
factors and cytokines, which regulate their growth, including 
platelet-activating factor-receptor (PAF-R), a G-protein coupled 
receptor expressed in various types of cell (3-5). The activation 
of PAF-R has been demonstrated to mediate diverse biological 
functions in response to various stimuli, including inflamma-
tion, immunosuppression and tumorigenesis (6-13).
Previous studies, including ours, have demonstrated that 
the activation of PAF-R positively modulates melanoma 
growth, either directly (9-12) or indirectly via host immuno-
modulation (13). However, in epithelial cell types, activation of 
PAF-R can increase cell death, induced by pro-oxidative stress 
reagents (14,15). As melanoma is highly resistant to chemo-
therapy and radiation therapy (16), identifying novel pathways 
that can augment cytotoxic agent effects may offer a promising 
therapeutic approach for melanoma.
Isothiocyanates (ITCs), which are present in cruciferous 
vegetables, including broccoli and cabbage, possess anti-carci-
nogenic properties (17,18). Benzyl isothiocyanate (BITC), an 
Expression of the platelet-activating factor receptor 
enhances benzyl isothiocyanate-induced apoptosis 
in murine and human melanoma cells
RAVI PRAKASH SAHU1,2
Departments of 1Pathology and Laboratory Medicine and 2Dermatology, 
Indiana University School of Medicine, Indianapolis, IN 46202, USA
Received March 11, 2014;  Accepted November 20, 2014
DOI: 10.3892/mmr.2015.3371
Correspondence to: Ravi Sahu, Indiana University School of 
Medicine, IB419, 975 Walnut Street, Indianapolis, IN 46202, USA
E-mail: rsahu@iupui.edu
Abbreviations: PAF, platelet-activating factor; PAF-R, PAF-receptor; 
CPAF, 1-hexadecyl-2-N-methylcarbamoyl-3-glycerophosphocholine; 
BITC, benzyl isothiocyanate; ROS, reactive oxygen species; 
FACS, fluorescence-activated cell sorting; mRNA, messenger 
RNA; PBS, phosphate-buffered saline; RT-qPCR, reverse 
transcription-quantitative polymerase chain reaction
Key words: apoptosis, benzyl isothiocyanate, melanoma, 
platelet-activating factor-receptor, reactive oxygen species
SAHU: BENZYL ISOTHIOCYANATE SUPPRESSES MELANOMA CELL GROWTH VIA THE PAF-R 395
analog of ITC suppresses the in vitro and in vivo growth of 
various types of cancer (19-22). In melanoma, BITC and other 
isoforms of ITCs, including allyl and phenyl isothiocyanates 
and sulforaphane, have been observed to inhibit melanoma 
cell growth via different mechanisms (23-27). Since many 
melanomas express functional PAF-Rs and the role of PAF-R 
in the BITC-mediated suppression of melanoma cells remain 
to be elucidated, the present study aimed to assess whether 
the expression of PAF-R can augment the BITC-mediated 
cytotoxic effects in melanoma cells.
Materials and methods
Reagents. A Qiagen RNeasy Mini kit for RNA extraction 
was purchased from Qiagen Sciences (Germantown, MD, 
USA), and the Super Script (R) First-Strand Synthesis system 
for cDNA synthesis was purchased from Invitrogen Life 
Technologies, Carlsbad, CA, USA). The PAF-R and GAPDH 
primers and the SYBR Green polymerase chain reaction (PCR) 
reagents were purchased from SABiosciences (Valencia, CA, 
USA). A caspase-3/7 activity assay kit was purchased from 
Promega Corporation (Madison, WI, USA). The WEB2086 
PAF-R antagonist, was purchased from Cayman Chemicals 
Co. (Ann Arbor, MI, USA). All other reagents were purchased 
from Sigma-Aldrich (St. Louis, MO, USA).
Cells. Murine B16 cells expressing PAF-R (B16-PAFR), empty 
vector (B16-MSCV) and human SK23MEL melanoma cells 
were maintained in RPMI-1640 media (Life Technologies, 
Grand Island, NY, USA) supplemented with 10% fetal bovine 
serum (HyClone, GE Healthcare Life Sciences, Logan, UT, 
USA) and 100 µg/ml mixture of penicillin and streptomycin 
(Lonza, Walkersville, MD, USA). Human SK5MEL cells were 
obtained from the American Type Culture Collection (ATCC; 
Manassas, VA, USA) and cultured in Eagle's minimum essen-
tial medium (ATCC) supplemented with 10% FBS and 100 µg/
ml mixture of penicillin and streptomycin.
Reverse transcription-quantitative PCR (RT-qPCR). The mRNA 
expression of PAF-R was analyzed in the human SK5MEL and 
SK23MEL cells using RT-qPCR and the expression levels were 
normalized with GAPDH, as described previously (8,13). The 
B16-PAF-R and B16-MSCV cells were used as positive and 
negative controls. Briefly, the cells were homogenized using an 
RLT buffer containing β-mercaptoethanol (Sigma-Aldrich), in a 
bullet blender (Next Advance, Inc., Averill Park, NY, USA) and 
carbide beads. The total RNA was extracted using an RNAeasy 
kit according to the manufacturer's instructions. The purified 
RNA was quantified using a Nano Drop 2000 (Thermo Fisher 
Scientific, Inc., Lafayette, CO, USA) and reverse transcribed 
with a Super Script cDNA synthesis kit containing random 
hexamers. The cDNA was analyzed for the PAF-R mRNA 
using a SYBR green-based, quantitative fluorescent PCR 
method (6‑8,13). The fluorescence was detected using a Step 
One Real-time PCR machine (Applied Biosystems, Foster City, 
CA, USA). The quantification of each PCR product was normal-
ized to GAPDH using the 2-ΔΔCt method.
Cell proliferation. The B16-PAF-R and B16-MSCV cells 
were plated in 24-well plates (20,000 cells/well) and treated 
with 1 or 10 nM 1-hexadecyl-2-N-methylcarbamoyl-3-glyc-
erophosphocholine (CPAF) and incubated for 24, 48 or 
72 h. The control cells received 0.1% ethanol dissolved in 
phosphate-buffered saline (PBS;10 µl) only. Following each 
time point, the cells were trypsinized, washed, resuspended 
in PBS and stained using 0.4% trypan blue according to the 
manufacturer's instructions (Invitrogen Life Technologies). 
The cell proliferation was assessed using a trypan blue exclu-
sion method and a Countess automated cell counter (Invitrogen 
Life Technologies).
Cell survival. The murine or human melanoma cells were 
seeded into 96-well plates (5,000 cells/well) and treated 
with various concentrations of BITC, as indicated in respec-
tive figures and figure legends. The control cells received 
0.1% dimethylsulfoxide (DMSO) treatment. The cell survival 
rate was assessed 24 h after treatment using a sulforhoda-
mine-B (SRB) assay, as described previously (19). The plates 
were read at 590nm using a Bio Kinetics plate reader (EL-800; 
BioTek Instruments, Inc., Winooski, VT, USA).
Reactive oxygen species (ROS) generation. The B16-MSCV 
and B16-PAF-R cells (1x105 cells/well) were seeded into 
6-well plates for attachment overnight. The cells were treated 
with H2DCFDA dye (DFC; 5 µM) for 30 min prior to treat-
ment with 2 µM BITC for 0, 5, 10 min or 1 h. In a separate 
experiment, the cells were pre -treated with vit amin C (5 mM) 
for 1 h prior to treatment with 2 µM BITC for 10 min. The 
control cells received 0.1% DMSO treatment. The generation of 
ROS was analyzed by measuring the number of DCF-positive 
cells using a flow associated cell sorter and FlowJo soft-
ware version 9.7.5 (Tree Star, Inc., Ashland, OR, USA).
Apoptosis. The B16-PAF-R and B16-MSCV cells 
(1x105 cells/well) were seeded into 6-well plates for attach-
ment overnight. The cells were then either pretreated with 
5 mM vitamin C or 10 µM WEB2086 PAF-R antagonist, 
for 1 h, followed by treatment with 2 µM BITC for 24 h. 
The control cells received 0.1% DMSO treatment. Apoptosis 
was quantified using a luminescence caspase‑3/7 glo-assay 
kit and normalized against the total protein, as described 
previously (28). The protein content of the samples were deter-
mined using a Bradford assay kit (Bio-Rad Laboratories, Inc., 
Hercules, CA, USA).
Statistical analysis. Each data set is representative of the 
combined results of at least three independent experiments 
with similar findings. Data were analyzed using GraphPad 
Prism software version 5 (GraphPad software, San Diego, CA, 
USA). Student's t-test and one-way analysis of variance with 
a Bonferroni Post -hoc test were used to compare two groups 
or more than two groups. P<0.05 was considered to indicate a 
statistically significant difference.
Results
Evaluation of the expression of PAF-R and the effect of CPAF 
the PAF-R agonist on melanoma cell growth. The majority of 
human melanoma cells express PAF-R, however, the B16F10 
murine melanoma cell line, does not (9,13). To determine 
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the role of the PAF-R, a B16-PAF-R cell line was created 
by transduction of PAF-R-negative B16F10 cells with the 
MSCV2.1 retrovirus encoding the human leukocyte PAF-R, 
as described previously (13). B16-MSCV cells were used as 
a control. The human melanoma cells were then screened 
for the presence of functional PAF-R. RT-qPCR revealed the 
presence of functional PAF-R in the human SK23MEL cells 
(Fig. 1A). By contrast, human melanoma SK5MEL cells defi-
cient in PAF-R were selected and used as a control (Fig. 1A). 
To evaluate the role of PAF-R in the progression of melanoma, 
the B16-PAF-R and B16-MSCV cells were treated with the 
non-metabolizable PAF-R agonist, CPAF, at different doses 
and time points prior to the assessment of cell proliferation. As 
shown in Fig. 1B, CPAF-treatment induced the proliferation 
of B16-PAF-R cells in a dose- and time-dependent manner, 
compared with the vehicle-treated B16-PAF-R cells. Notably, 
CPAF had no effect on the proliferation of the B16-MSCV 
cells at these doses, suggesting that PAF-R was involved in 
melanoma cell growth.
Effect of the BITC-mediated cytotoxicity of melanoma cells 
with regards to the PAF-R. Previous studies have demon-
strated that ITC analogs, including BITC, exhibit decreased 
cytotoxicity towards melanoma cells in vitro (half maximal 
inhibitory concentration 10-20 µM), indicating that higher 
concentrations are required to achieve efficacy (29). The 
present study aimed to determine the effect of PAF-R on 
the BITC-mediated cytotoxicity of melanoma cells. The 
relative cytotoxicity of BITC in the melanoma cells was 
compared in the presence or absence of functional PAF-R 
using murine and human melanoma cells. PAF-R positive, 
B16-PAF-R and SK23MEL and PAF-R negative, B16-MSCV 
and SK5MEL cells were treated with different concentra-
tions of BITC for 24 h and cell survival was measured. As 
shown in Fig. 2A and B, BITC dose-dependently reduced 
the survival of these cells. However, the expression of the 
PAF-R augmented the BITC-induced cytotoxicity in the 
B16-PAF-R (IC50 ~2 mM) and SK23MEL (IC50 ~6 mM) 
cells, compared with the PAF‑R deficient cells. The IC50 
of BITC in PAF‑R deficient murine B16‑MSCV cells was 
~11 mM and in the human SK5MEL cells was >50 µM. 
These findings indicated that PAF‑R signaling augments the 
decreased survival of the melanoma cells, which is elicited 
by BITC, at a lower concentration than is required for the 
PAF‑R‑deficient cells.
BITC treatment enhances the generation of ROS in 
PAF-R-expressing melanoma cells. BITC acts as a 
pro-oxidative stressor, inducing the generation of ROS as 
a potent mechanism of tumor cell death (21,22,24,30-32). 
By contrast, other studies have demonstrated that BITC can 
also mediate potent antioxidant effects against oxidized low 
density lipoprotein-induced endothelial dysfunction (33) and 
inflammation‑mediated carcinogenesis (34,35). To determine 
the mechanism underlying the BITC-induced decreased 
survival rate of the PAF-R expressing melanoma cells, the 
effect of BITC on ROS generation was measured. For mecha-
nistic studies, B16-PAF-R and B16-MSCV cells were used 
as these lines were generated from the same parent (B16F10) 
cells. As the IC50 of BITC in the B16-PAF-R cells was ~2 µM, 
Figure 1. Effect of the PAF-R status on the proliferation of melanoma cells. (A) Evaluation of the presence of PAF-R status using reverse transcription-qPCR 
in murine and human melanoma cells. (B) B16-PAF-R and B16-MSCV cells were seeded into 24-well plates (20,000 cells/well) and allowed to attach 
overnight. The cells were treated with either vehicle or 1 or 10nM CPAF PAF-R agonist and cultured for 1, 2 or 3 days. At each time point, the cells were 
trypsinized and the number of cells were counted using a trypan blue exclusion method. Data are expressed as the mean ± standard deviation of the cell 
proliferation by CPAF over the number of days. Statistically significant differences were observed between the B16‑MSCV and B16‑PAF‑R cells at 10nM 
CPAF on days 1, 2 and 3 (***P<0.001 and **P<0.01 vs. MSCV + 10 nM group). No significant differences were observed in the baseline growth rate between 
the B16-MSCV and B16-PAF-R cells. PAF-R, platelet-activating factor-receptor; MSCV, empty vector; qPCR, quantitative polymerase chain reaction; CPAF, 
1-hexadecyl-2-N-methylcarbamoyl-3-glycerophosphocholine, VEH, vehicle. 
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this concentration of BITC was used to treat the B16-PAF-R 
and B16-MSCV cells at different time points. The cells were 
pretreated with the antioxidant, vitamin C (5 mM) for 1 h and 
subsequently with BITC. As shown in Fig. 3A, BITC treat-
ment induced a significant increase in ROS generation in 
each of the cell lines. However, in the B16-PAF-R cells, ROS 
generation occurred as early as 5 min after treatment and was 
significantly increased compared with the B16‑MSCV cells 
at all time points (Fig. 3A). Treatment with vitamin C inhib-
ited the BITC-induced ROS generation (Fig. 3A) and rescued 
B16-PAF-R cells (Fig. 3B), indicating a role for ROS in the 
BITC-induced suppression of the B16-PAF-R cells.
PAF-R augments BITC-induced apoptosis in the B16-PAF-R 
cells. The induction of apoptosis in malignant cells has been 
revealed as a major mechanism of chemopreventive/thera-
peutic drug-mediated cell death (12,15,19,30-33). To determine 
whether the expression of PAF-R augments the BITC-mediated 
decrease in B16-PAF-R cell survival via ROS generation, apop-
tosis induction was measured. The B16-PAF-R and B16-MSCV 
cells were treated with 2 µM BITC for 24 h in the presence or 
absence of either vitamin C or the WEB2086 PAF-R antagonist. 
As shown in Fig. 4, BITC‑treatment resulted in a significant 
apoptotic response in the B16-PAF-R cells compared with the 
B16-MSCV cells. The induction of apoptosis in the B16-PAF-R 
Figure 2. Effect of the expression of PAF-R on the BITC-mediated suppression of murine and human melanoma cell survival. (A and B) B16-PAF-R, 
B16-MSCV, SK23MEL and SK5MEL cells were treated with either vehicle (0.1% DMSO) or different concentrations of BITC in vitro and incubated for 24 h. 
The cell survival was measured following incubation using an sulforhodamine-B assay. Data are expressed as the mean ± standard deviation and are presented 
as the percent survival against the BITC treatments. MSCV, empty vector; PAF-R, platelet-activating factor-receptor; BITC, benzyl isothiocyanate; DMSO, 
dimethylsulfoxide; IC50, half maximal inhibitory concentration.
 A  B
Figure 3. Effect of BITC on the generation of ROS in melanoma cells (A) Effect of BITC treatment (2 µM) on the generation of ROS in the presence and 
absence of Vit C (5 mM) was analyzed by measuring DCF fluorescence by flow cytometry. Data are represented as the mean ± standard deviation and are 
presented as the generation of ROS against the different treatment groups. Statistically significant differences were observed between the vehicle and BITC 
treatment groups and the BITC and vit C + BITC groups (*P<0.05; £P<0.01, $P<0.001, **P<0.01 and ***P<0.001). (B) The effect of BITC on cell survival 
rates in the presence and absence of vit C (5 mM) in the B16-PAF-R and B16-MSCV cells was determined using an SRB assay. Data are expressed as the 
mean ± standard deviation and presented as the percent survival against the different treatment groups. Statistically significant differences were observed 
between the vehicle and the BITC treated groups and the BITC and vitamin C + BITC treated group (***P<0.001; $P<0.001). The control cells received vehicle 
(DMSO) treatment only. Veh, vehicle; BITC, benzyl isothiocyanate; MSCV, empty vector; PAF-R, platelet-activating factor-receptor; ROS, reactive oxygen 
species; Vit C, vitamin C. 
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cells was significantly attenuated following treatment with 
vitamin C and WEB2086. These results indicated the involve-
ment of PAF-R signaling in the BITC-induced decrease in 
growth of the B16-PAF-R cells mediated via increased ROS 
generation and induction of apoptosis.
Discussion
The activation of PAF-R is important in diverse biological 
processes, including regulating the growth of melanoma (3-13), 
and the majority of types of melanoma express PAF-R (9) and 
are resistant to the currently used chemotherapeutic agents (16). 
Therefore, the present study investigated the efficacy of BITC 
against melanoma cells, in those either expressing PAF-R or 
not. Human melanoma cells, either deficient in or expressing 
PAF-R, and murine melanoma B16F10 cells, which have been 
extensively used in chemotherapy studies and lack functional 
PAF‑R expression, were genetically modified to produce cells 
stably expressing PAF-R or vector-controls as suitable model 
systems.
Treatment with CPAF increased the proliferation of the 
PAF-R-expressing B16-PAF-R cells in a dose- and time-depen-
dent manner compared with the B16‑MSCV cells, confirming 
that PAF-R activation enhances the growth of melanoma 
cells. By contrast, BITC-treatment reduced the survival rate 
of the murine and human melanoma cells in a dose-dependent 
manner. However, the presence of functional PAF-R potenti-
ated the cytotoxicity of BITC in the B16-PAF-R murine and 
human SK23MEL melanoma cells, requiring relatively lower 
doses than were required for the PAF‑R deficient cells. This 
indicated that the expression of PAF-R results in enhanced 
cytotoxicity of the melanoma cells by BITC.
Generation of ROS is an early event following chemo-
therapy, that is important in inducing apoptosis in malignant 
cells (15,30-32). In this context, treatment with BITC at doses 
that substantially reduced the survival of the B16-PAF-R 
cells, increased the generation of ROS and the levels of 
apoptosis compared with the B16-MSCV cells. These effects 
were attenuated by vitamin C, suggesting the involvement of 
ROS in the BITC-induced decreased survival of B16-PAF-R 
cells. These data are consistent with previous studies, which 
demonstrated that the BITC-induced suppression of malignant 
cells was mediated via ROS generation and inhibited by free 
radical quenchers (30). The present study demonstrated that 
BITC-treatment resulted in an increased level of apoptosis of 
the B16‑PAF‑R cells via ROS and confirmed the role of the 
PAF-R activation. The BITC-induced increase in apoptosis in 
the B16-PAF-R cells was inhibited by the WEB2086 PAF-R 
antagonist, confirming the involvement of PAF‑R signaling 
in this process. The ability of PAF-R signaling to promote 
the proliferation of the B16-PAF-R cells and to augment 
BITC-mediated apoptosis was in agreement with previous 
studies, which observed that CPAF-treatment induced 
increased proliferation in a PAF-R-negative KB epithelial 
cell line, which was genetically modified to stably express the 
functional PAF-R (KBP), however this did not occur in retro-
viral vector-transduced control KBM cells (36). Similarly, the 
expression of PAF-R augmented ultraviolet B (UVB)-mediated 
apoptosis of PAF-R-positive KBP but not PAF-R-negative 
KBM cells (14). This increased susceptibility of the KBP cells 
towards UVB-mediated enhanced apoptosis was inhibited 
by antioxidants and PAF-R antagonists. Additionally, PAF-R 
activation augmented chemotherapy-induced cytotoxicity 
in human carcinoma cell lines (15). These previous studies 
confirm the involvement of the PAF‑R signaling in mediating 
pro-oxidative stressors including BITC-mediated increase in 
melanoma cell apoptosis.
In conclusion, naturally occurring ITCs have been demon-
strated to possess anticarcinogenic properties, however, the 
lack of specific oncogenic targets and the use of higher concen-
trations to achieve optimum therapeutic efficacy have made 
them unsuitable. Therefore, the selection of potent analogs, 
which can target specific signaling pathways may offer more 
effective agents against malignant cells. The present study 
demonstrated that BITC suppressed the growth of melanoma 
cells and that this was augmented by the activation of PAF-R 
through the ROS-mediated pathway. Collectively, these data 
suggest that BITC may be used as a novel chemotherapeutic 
agent against PAF-R-expressing melanoma cells.
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